|
Evaluation of completeness of commonly used data elements for clinical trial eligibility criteria using a registry-enhanced data collection process: Results from patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) at three community oncology practices. |
|
Annette Campbell Fontaine |
Employment - New Mexico Cancer Center |
Leadership - New Mexico Cancer Center; New Mexico Cancer Center (Inst) |
|
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca |
Speakers' Bureau - Stemline Therapeutics (Inst) |
Research Funding - Daiichi Sankyo (Inst) |
Travel, Accommodations, Expenses - Daiichi Sankyo |
|
|
Employment - New Mexico Oncology Hematology Consultants LTD |
Leadership - National Cancer Care Alliance (NCCA) |
Patents, Royalties, Other Intellectual Property - Triage pathways of IOBs |
Travel, Accommodations, Expenses - various associations |
|
|
Employment - New Mexico Oncology Hematology Ltd. |
Travel, Accommodations, Expenses - New Mexico Oncology Hematology Ltd. |
|
|
Stock and Other Ownership Interests - Merck |
|
|
No Relationships to Disclose |
|
|
Employment - Genentech; N-Power Medicine |
Stock and Other Ownership Interests - N-Power Medicine; Roche/Genentech |
Patents, Royalties, Other Intellectual Property - Patents pending: WO2022031749A1, WO2016024213A3, WO2022032257A1, US20220028549A1 |
|
|
Employment - N-Power Medicine |
Stock and Other Ownership Interests - Pendulum Therapeutics |
Patents, Royalties, Other Intellectual Property - Pendulum Therapeutics |
|
|
Employment - Foundation Medicine; Lexent Bio; N-Power Medicine |
Stock and Other Ownership Interests - Foundation Medicine; Foundation Medicine (I); Lexent Bio; N-Power Medicine; N-Power Medicine (I) |
|
|
Employment - Oncology Consultants |
Leadership - Oncology Consultants |
Stock and Other Ownership Interests - Consultores en Oncologia; Oncology Consultants; zogen |
Consulting or Advisory Role - Exigent Research Network |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BerGenBio (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Genentech/Roche (Inst); ImmunityBio (Inst); Immutep (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); OncoC4 (Inst); QSAM (Inst); Seagen (Inst); Sermonix Pharmaceuticals (Inst); Systimmune (Inst) |
|
|
Research Funding - N-Power Medicine (Inst) |